Aspen Neuroscience (ASPE) closed at $13.82 on November 11, 2026, up 7.9% from the previous close, on volume of 282,936 shares (30-day average 448,638).
Data as of November 11, 2026.
No headlines found.
No press releases found.
No news found.
Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.
Aspen Neuroscience trades on the NASDAQ stock market under the symbol ASPE.
As of November 12, 2026, ASPE stock price declined to $13.37 with 168,748 million shares trading.
ASPE has a market cap of $388.78 million. This is considered a Small Cap stock.
ASPE support price is $12.61 and resistance is $15.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASPE shares will trade within this expected range on the day.
